As a core enterprise under the pharmaceutical and healthcare division of China Grand Enterprises, Inc., Grand Life Sciences Group Co., Ltd. (hereinafter referred to as "Grand Life Sciences") is an international pharmaceutical and healthcare enterprise driven by innovation and supported by a robust industrial foundation. Over the years, Grand Life Sciences has established an integrated industrial presence in five key areas: blood products, probiotics, vaccines, medical nutrition, and perioperative care.

Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang"), a wholly-owned subsidiary of Grand Life Sciences Group Co., Ltd., traces its origins to the Plasma Research Institute of the Chengdu Military Region Logistics Department, established in 1969. In 1985, Chengdu Shuyang Pharmaceutical Factory was officially founded, making it one of the first enterprises in China to receive approval from the Ministry of Health for large-scale industrial production of blood products. In 1998, the factory was transferred from the Chengdu Military Region Logistics Department to the Chengdu Municipal Government and joined China Grand Enterprises, Inc. in 2001. Over the past half-century, Grand Shuyang has continuously innovated and advanced, solidifying its position as a leading high-tech enterprise in China's blood products industry.

Grand Shuyang has developed a comprehensive R&D capability platform, evolving from blood sourcing to recombinant technology. Its product portfolio encompasses three major categories: albumin, immunoglobulins, and coagulation factors, making it one of the most versatile and plasma-efficient companies in China's blood products sector. Grand Shuyang has established a globally leading Industry 4.0 intelligent manufacturing base for blood products, enabling full coverage of market demands across the entire product chain and positioning itself as a world-class industrial base for blood products. The Company holds exclusive commercial rights in China for the global innovative hemophilia treatment, Tissue Factor Pathway Inhibitor (TFPI) monoclonal antibody KN057, which has initiated two Phase III clinical trials in China and wans granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2024.

Moving forward, Grand Shuyang remains committed to a development path of "high-quality standards, comprehensive product coverage, and market internationalization". It aims to consolidate the driving forces for industry advancement and harness synergy for rapid growth, striving to become a "full-product-chain international premium service provider in the blood products sector" to safeguard human health, enhance the quality of life, and co-create a better future.